REGENSBURG, GERMANY -- 09/08/08 --
- GENEART increases sales activities in its key foreign market
- Founding of a new sales office in San Francisco (California, USA)
is completed
- GENEART positions itself in the vicinity of customers on the west
coast, with research budgets of more than USD 12 billion
Regensburg, September 8, 2008 - GENEART AG, the global leader in gene
synthesis and specialist in the field of Synthetic Biology, has
announced the founding of a new subsidiary on the west coast of the
USA in San Francisco, California. The newly-founded subsidiary
GENEART Inc. is located in the San Francisco Bay Area, at the heart
of one of the largest biotech clusters in the world. More than 140
listed biotechnology companies in California generate annual sales of
approximately USD 44 billion and spend more than USD 12 billion on
research and development.* In addition to the large number of
biopharmaceutical/biotechnology firms and large research centers,
numerous renowned academic research institutions along the west coast
of the U.S. are working on the development of new industrial products
and therapeutics. "With our two subsidiaries in Toronto, Canada and
San Francisco, U.S., we can now offer optimum support for the largest
biotechnology research clusters in North America. This benefits all
researchers in the pharmaceutical and biotechnology industries as
well as academic institutions working on the development of
innovative biopharmaceuticals, vaccines and industrial enzymes.
Direct contact to our customers and outstanding customer service are
key factors for continued strong growth in North America, our most
important foreign market," says Christian Ehl, CEO of GENEART AG.
* From "Beyond Borders", Ernst & Young 2008
For further inquiries, please contact:
Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com
Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de
Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001-2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. The GENEART
AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto
(Canada) employ more than 190 people. Since May 2006, GENEART is
listed on the German Stock Exchange.
GENEART Founds a Subsidiary in the West Coast of the US :
http://hugin.info/136633/R/1248829/270873.pdf
Copyright © Hugin AS 2008. All rights reserved.
